Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (31-40 of 299) with videos related to

Pageof 30
Sort By:
Current Opinion in Oncology|September 28, 2012
Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancerDimitrios Zardavas, Ivana Bozovic-Spasojevic, Evandro de Azambuja
Breast Cancer Research and Treatment|October 1, 2024
Response to letter "re: Surgery of the primary tumor in patients with de novo metastatic breast cancer: A nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)"Diogo Martins-Branco, Mariana Brandão, Evandro de Azambuja
Clinical Advances in Hematology & Oncology : H&O|November 6, 2007
Trastuzumab for early breast cancer: current status and future directionsPhuong Dinh, Evandro de Azambuja, Martine J Piccart-Gebhart
Oncotarget|March 9, 2019
Oncofertility counselling in premenopausal women with HER2-positive breast cancerMatteo Lambertini, Isabelle Demeestere, Giulia Viglietti, et al.
Breast Care (Basel, Switzerland)|January 14, 2014
How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast CancerAna Catarina Pinto, Evandro de Azambuja, Martine Piccart-Gebhart
Current Oncology Reports|March 25, 2021
Emerging Therapeutics for Patients with Triple-Negative Breast CancerElisa Agostinetto, Daniel Eiger, Kevin Punie, et al.
Expert Review of Anticancer Therapy|November 25, 2016
Adjuvant trastuzumab: a 10-year overview of its benefitMatteo Lambertini, Noam F Pondé, Cinzia Solinas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemmaFabio Puglisi, Evandro de Azambuja, Gilberto de Castro, et al.
Expert Opinion on Investigational Drugs|July 17, 2009
Larotaxel: broadening the road with new taxanesOtto Metzger-Filho, Camilo Moulin, Evandro de Azambuja, et al.
Cancers|April 3, 2021
The Exciting New Field of HER2-Low Breast Cancer TreatmentDaniel Eiger, Elisa Agostinetto, Rita Saúde-Conde, et al.
Pageof 30

Showing results (31-40 of 299) with videos related to

Sort By:
Pageof 30
Current Opinion in Oncology|September 28, 2012
Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancerDimitrios Zardavas, Ivana Bozovic-Spasojevic, Evandro de Azambuja
Breast Cancer Research and Treatment|October 1, 2024
Response to letter "re: Surgery of the primary tumor in patients with de novo metastatic breast cancer: A nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)"Diogo Martins-Branco, Mariana Brandão, Evandro de Azambuja
Clinical Advances in Hematology & Oncology : H&O|November 6, 2007
Trastuzumab for early breast cancer: current status and future directionsPhuong Dinh, Evandro de Azambuja, Martine J Piccart-Gebhart
Oncotarget|March 9, 2019
Oncofertility counselling in premenopausal women with HER2-positive breast cancerMatteo Lambertini, Isabelle Demeestere, Giulia Viglietti, et al.
Breast Care (Basel, Switzerland)|January 14, 2014
How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast CancerAna Catarina Pinto, Evandro de Azambuja, Martine Piccart-Gebhart
Current Oncology Reports|March 25, 2021
Emerging Therapeutics for Patients with Triple-Negative Breast CancerElisa Agostinetto, Daniel Eiger, Kevin Punie, et al.
Expert Review of Anticancer Therapy|November 25, 2016
Adjuvant trastuzumab: a 10-year overview of its benefitMatteo Lambertini, Noam F Pondé, Cinzia Solinas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemmaFabio Puglisi, Evandro de Azambuja, Gilberto de Castro, et al.
Expert Opinion on Investigational Drugs|July 17, 2009
Larotaxel: broadening the road with new taxanesOtto Metzger-Filho, Camilo Moulin, Evandro de Azambuja, et al.
Cancers|April 3, 2021
The Exciting New Field of HER2-Low Breast Cancer TreatmentDaniel Eiger, Elisa Agostinetto, Rita Saúde-Conde, et al.
Pageof 30